新辅助化疗对乳腺癌雌激素受体和HER-2的影响及意义

目的]探讨雌激素受体（ER）和HER-2在新辅助化疗乳腺癌组织的表达及临床意义。方法]采用免疫组织化学方法检测100例乳腺癌患者新辅助化疗前后肿瘤组织中ER及HER-2的表达,并与疗效作相关性分析。结果]新辅助化疗总有效率79%,ER阴性表达者化疗有效率明显高于ER阳性者（P〈0.05）,HER-2表达与疗效无明显关系（P〉0.05）。化疗后ER、HER-2的表达未见显著性变化（P〉0.05）。结论]新辅助化疗对ER、HER-2表达状态无显著影响。ER对乳腺癌新辅助化疗疗效有一定预测价值。

Effect of Neoadjuvant Chemotherapy on Expression of ER,HER-2 in Breast Cancer and Their Significance

Purpose] To investigate the expression of ER and HER-2 in breast cancer tissue and its clinical significance. Methods] Expressions of ER, HER-2 in 100 cases patients with breast cancer were detected by immunohistochemistry before and after neoadjuvant chemotherapy. The relationship of ER and HER-2 with response of neoadjuvant chemotherapy was analyzed. Results] The overall response rate of neoadjuvant chemotherapy was 79%. Response rate in patients with negative expression of ER was higher than that with positive expression of ER（P〈0.05）. There was no significant relation between the response and HER-2 expression（P〉0.05）. Expression of ER and HER-2 did not change significantly after neoadjuvant chemotherapy （P〈0.05）. Conclusion] Neoadjuvant chemotherapy did not significantly influence on status of ER and HER-2. ER may be used to predict the therapeutic response of neoadjuvant chemotherapy in breast cancer.